Hall Laurie J Trustee Decreases Position in Solventum Corporation $SOLV

Hall Laurie J Trustee lowered its stake in shares of Solventum Corporation (NYSE:SOLV) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,549 shares of the company’s stock after selling 264 shares during the period. Hall Laurie J Trustee’s holdings in Solventum were worth $346,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Trian Fund Management L.P. increased its stake in shares of Solventum by 18.8% during the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company’s stock worth $559,054,000 after purchasing an additional 1,336,564 shares during the last quarter. Independent Franchise Partners LLP grew its stake in Solventum by 263.1% in the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after buying an additional 4,217,570 shares in the last quarter. Davis Selected Advisers grew its stake in Solventum by 0.8% in the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock valued at $402,110,000 after buying an additional 41,524 shares in the last quarter. Boston Partners grew its stake in Solventum by 101.3% in the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after buying an additional 1,691,565 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Solventum by 3.3% in the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after buying an additional 58,373 shares in the last quarter.

Solventum Stock Performance

NYSE SOLV opened at $71.33 on Thursday. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $85.92. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The company has a market capitalization of $12.37 billion, a P/E ratio of 33.02, a P/E/G ratio of 1.77 and a beta of 0.53. The company has a fifty day moving average of $73.63 and a 200-day moving average of $72.79.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the previous year, the firm posted $1.56 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analysts Set New Price Targets

SOLV has been the subject of a number of recent research reports. Wells Fargo & Company lifted their price objective on shares of Solventum from $75.00 to $79.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. KeyCorp initiated coverage on shares of Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating for the company. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a research note on Tuesday, July 1st. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Piper Sandler restated an “overweight” rating and set a $94.00 price target (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $85.75.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.